Browse Items (2 total)
- Tags: Stephenson T
Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old
Tags: 2005, a good or excellent result was obtained in 93% of the domperidone group compared with 33% of the controls (P < 0.05). In the trial undertaken by de Loore, after 2 weeks of treatment 75% of patients treated with domperidone were found not to be vomiting, and reference citations of the RCTs that had been found electronically. RESULTS: Four RCTs were identified. Only the two older trials showed any benefits of domperidone on clinical symptoms of GORD in older children, Antiemetics/therapeutic use Child Child, Baber N, Backlog, British Journal of Clinical Pharmacology, compared with 43% in the metoclopramide group and 7% in the placebo group. The trial by Corraccio gave no detailed results regarding the primary outcomes of effect of domperidone on symptoms but simply reported 'cured', drug therapy Humans Infant Randomized Controlled Trials/methods Research Design Treatment Outcome, Journal Article, Medline (Pub-med) 1966 to present and Embase from 1974 to 2004, PedPal Lit, Preschool Domperidone/, Pritchard DS, Stephenson T, the widespread use of unlicensed medicines for GOR is not warranted., therapeutic use Dopamine Antagonists/, therapeutic use Evidence-Based Medicine Gastroesophageal Reflux/, there was no robust evidence of efficacy for the treatment of GOR with domperidone in young children. Given the usually benign nature of the condition, was reduced with domperidone. CONCLUSION: From the limited evidence available, which were the primary outcome measures. In the trial undertaken by Clara
Tags: 2005, a drug - a truly age-dependent difference in pharmacodynamics. This may be true of both the desired action and adverse events. Examples are given. Programming by drugs is also a phenomenon almost exclusive to early life, Adult Aging/metabolism Bayes Theorem Child Clinical Trials/methods Humans PharmacogeneticsPharmacokinetics Research Design%X Children are not small adults. However, and response to, Backlog, British Journal of Clinical Pharmacology, different 'host' response and different adverse drug reactions can all explain why some drugs behave differently in children. However, different disease variants, different pharmacodynamics, example s are discussed. Different pathophysiology, i.e. permanent effects result from a stimulus applied at a sensitive point in development ('critical window'), Journal Article, often in fetal or neonatal life. Again, PedPal Lit, stage of development can alter the action of, Stephenson T, the main thesis of this review will be that children's responses to drugs have much in common with the responses in adults and indeed in other mammals. Often, we need to explore ways to avoid re-inventing the wheel by determining how data from adult animal and human models can help inform research and practice for children.